Dyadic’s Platform Powers Productivity & Profit | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20065491

Show notes

Dyadic International is on a high-growth trajectory, slashing costs by 40% and boosting productivity 80% with its animal-free recombinant human transferrin — a win that’s turbocharging their entire platform. They’re landing major deals, shipping to IBT Bioservices, and making initial sales in cultivated meat. By partnering with established distributors, they’re keeping their commercial team lean while expanding into food and nutrition with non-animal bovine chymosin and more royalties on the horizon. Fermbox Bio is scaling up too, showing multiple stages of commercialization. Dyadic is also leveraging optimized strains across research, cell culture, and new markets for faster validation and revenue. With near-term sales and externally funded biopharma programs generating critical data, they’re building a balanced, recurring-revenue business poised for strategic wins. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/d0c2d9780d04234a

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.